Europe Melanoma Epidemiology and Patient Flow Analysis - 2017
Fore Pharma announced the results of its Melanoma patients study in a new report ‘Europe Melanoma Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Melanoma epidemiology, Melanoma diagnosed patients, and Melanoma treatment rate for EU5 pharmaceutical markets. The study measures key indicators such as prevalence of Melanoma derived from epidemiological analysis, percentage of patients diagnosed with Melanoma, and percentage of patients treated with a therapy.
The study helps executives estimate Melanoma market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Melanoma prevalence, Melanoma diagnosis rate, and Melanoma treatment rate for the period 2016 - 2025. The information is presented by leading geographies including Germany, France, Spain, Italy, and UK. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.
Key Features of the Report:
- Melanoma Patient Flow
- Melanoma Prevalence
- Melanoma Diagnosed Patients
- Melanoma Treated Patients
- 1. Melanoma: Disease Definition
- 2. Melanoma Patient Flow in Europe
- 2A. Melanoma Prevalence in Europe
- 2B. Melanoma Diagnosed Patients in Europe
- 2C. Melanoma Treated Patients in Europe
- 3. Melanoma Patient Flow in Germany
- 3A. Melanoma Prevalence in Germany
- 3B. Melanoma Diagnosed Patients in Germany
- 3C. Melanoma Treated Patients in Germany
- 4. Melanoma Patient Flow in France
- 4A. Melanoma Prevalence in France
- 4B. Melanoma Diagnosed Patients in France
- 4C. Melanoma Treated Patients in France
- 5. Melanoma Patient Flow in Spain
- 5A. Melanoma Prevalence in Spain
- 5B. Melanoma Diagnosed Patients in Spain
- 5C. Melanoma Treated Patients in Spain
- 6. Melanoma Patient Flow in Italy
- 6A. Melanoma Prevalence in Italy
- 6B. Melanoma Diagnosed Patients in Italy
- 6C. Melanoma Treated Patients in Italy
- 7. Melanoma Patient Flow in UK
- 7A. Melanoma Prevalence in UK
- 7B. Melanoma Diagnosed Patients in UK
- 7C. Melanoma Treated Patients in UK
- 8. Research Methodology
- List of Tables
- Table 1: Melanoma Patient Flow in Europe, 2016
- Table 2: Melanoma Patient Flow Forecast in Europe, 2016 - 2025
- Table 3: Melanoma Patient Flow in Germany, 2016
- Table 4: Melanoma Patient Flow Forecast in Germany, 2016 - 2025
- Table 5: Melanoma Patient Flow in France, 2016
- Table 6: Melanoma Patient Flow Forecast in France, 2016 - 2025
- Table 7: Melanoma Patient Flow in Spain, 2016
- Table 8: Melanoma Patient Flow Forecast in Spain, 2016 - 2025
- Table 9: Melanoma Patient Flow in Italy, 2016
- Table 10: Melanoma Patient Flow Forecast in Italy, 2016 - 2025
- Table 11: Melanoma Patient Flow in UK, 2016
- Table 12: Melanoma Patient Flow Forecast in UK, 2016 - 2025
- List of Figures
- Figure 1: Melanoma Patient Flow in Europe, 2016
- Figure 2: Melanoma Patient Flow Forecast in Europe, 2016 - 2025
- Figure 3: Melanoma Patient Flow in Germany, 2016
- Figure 4: Melanoma Patient Flow Forecast in Germany, 2016 - 2025
- Figure 5: Melanoma Patient Flow in France, 2016
- Figure 6: Melanoma Patient Flow Forecast in France, 2016 - 2025
- Figure 7: Melanoma Patient Flow in Spain, 2016
- Figure 8: Melanoma Patient Flow Forecast in Spain, 2016 - 2025
- Figure 9: Melanoma Patient Flow in Italy, 2016
- Figure 10: Melanoma Patient Flow Forecast in Italy, 2016 - 2025
- Figure 11: Melanoma Patient Flow in UK, 2016
- Figure 12: Melanoma Patient Flow Forecast in UK, 2016 - 2025
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
